← Back to Search

Monoclonal Antibodies

Chemotherapy + Bevacizumab + Atezolizumab for Colorectal Cancer

Phase 3
Recruiting
Led By Caio Max S Rocha Lima
Research Sponsored by National Cancer Institute (NCI)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Documentation by PET/CT scan, CT scan, or MRI that the patient has measurable metastatic disease per RECIST 1.1
Tumor must be determined to be mismatch-repair deficient (dMMR) or MSI-H
Must not have
Administration of a live, attenuated vaccine within 28 days prior to randomization
Documented New York Heart Association (NYHA) class III or IV congestive heart failure
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Pivotal Trial
No Placebo-Only Group

Summary

This trial is testing a combination of chemotherapy drugs, bevacizumab, and atezolizumab to treat patients with metastatic colorectal cancer.

Who is the study for?
This trial is for adults with metastatic colorectal cancer that hasn't been treated systemically. They must have a certain type of tumor (dMMR or MSI-H), adequate organ function, and no recent heart issues or severe infections. Participants need to agree to use effective contraception and not be pregnant.
What is being tested?
The study tests how well a combination of chemotherapy drugs (fluorouracil, oxaliplatin, leucovorin) works with Bevacizumab and/or Atezolizumab in treating metastatic colorectal cancer. It looks at the effects on tumors that don't repair DNA mistakes well.
What are the potential side effects?
Possible side effects include fatigue, increased risk of infection, bleeding complications, allergic reactions to treatment components, high blood pressure, nerve damage symptoms like numbness or tingling in hands and feet.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My scans show measurable cancer spread.
Select...
My tumor is identified as mismatch-repair deficient or has high microsatellite instability.
Select...
I have metastatic colon or rectal cancer and haven't received chemotherapy for it.
Select...
I am 18 years old or older.
Select...
I can take care of myself and am up and about more than half of my waking hours.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have not received a live vaccine in the last 28 days.
Select...
I have severe heart failure (NYHA class III or IV).
Select...
I have a significant liver condition.
Select...
I have not had a severe infection in the last 28 days.
Select...
I have not had major surgery or a significant injury in the last 28 days.
Select...
My high blood pressure is not under control.
Select...
I have a history of lung conditions.
Select...
I have a skin condition that meets certain criteria.
Select...
I do not have active tuberculosis.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Progression free survival (PFS)
Secondary study objectives
Chromium
Duration of SD
Duration of overall response (CR or PR)
+3 more
Other study objectives
Change in T-cell diversity
Change in quantification of cell free deoxyribonucleic acid (cfDNA) mutations
Changes in T-cell repertoire diversity as a predictive biomarker of efficacy
+10 more

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Arm III (atezolizumab, bevacizumab, mFOLFOX6)Experimental Treatment11 Interventions
Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive bevacizumab IV over 30-90 minutes on day 1, oxaliplatin IV over 2 hours on day 1 cycles 1-10, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on day 1. Treatment with oxaliplatin repeats every 2 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity. Treatment of bevacizumab, leucovorin calcium, and fluorouracil repeat every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with or without PET or MRI throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial.
Group II: Arm II (atezolizumab)Experimental Treatment7 Interventions
Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with or without PET or MRI throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial.
Group III: Arm I (bevacizumab, mFOLFOX6)Active Control10 Interventions
Patients receive bevacizumab intravenously (IV) over 30-90 minutes on day 1, oxaliplatin IV over 2 hours on day 1 of cycles 1-10, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1 and 2. Treatment with oxaliplatin repeats every 2 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity. Treatment of bevacizumab, leucovorin calcium, and fluorouracil repeat every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with or without PET or MRI throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial. (CLOSED TO ACCRUAL)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bevacizumab
2013
Completed Phase 4
~5540
Positron Emission Tomography
2011
Completed Phase 2
~2200
Atezolizumab
2017
Completed Phase 3
~5850
Biospecimen Collection
2004
Completed Phase 3
~2020
Computed Tomography
2017
Completed Phase 2
~2740
Fluorouracil
2014
Completed Phase 3
~11700
Leucovorin
2005
Completed Phase 4
~6010
Magnetic Resonance Imaging
2017
Completed Phase 3
~1160
Oxaliplatin
2011
Completed Phase 4
~2890

Find a Location

Who is running the clinical trial?

NRG OncologyOTHER
237 Previous Clinical Trials
102,654 Total Patients Enrolled
National Cancer Institute (NCI)Lead Sponsor
13,906 Previous Clinical Trials
41,016,679 Total Patients Enrolled
Caio Max S Rocha LimaPrincipal InvestigatorNRG Oncology

Media Library

Atezolizumab (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT02997228 — Phase 3
Colon Cancer Research Study Groups: Arm III (atezolizumab, bevacizumab, mFOLFOX6), Arm I (bevacizumab, mFOLFOX6), Arm II (atezolizumab)
Colon Cancer Clinical Trial 2023: Atezolizumab Highlights & Side Effects. Trial Name: NCT02997228 — Phase 3
Atezolizumab (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02997228 — Phase 3
Colon Cancer Patient Testimony for trial: Trial Name: NCT02997228 — Phase 3
~1 spots leftby Nov 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top